podcasts
Overcoming obstacles in personalised medicine
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
List view / Grid view
Neurodegenerative diseases
news
Key enzyme discovery marks a step forward in Alzheimer’s treatment
Scientists have decoded the 3D structure of a key enzyme linked to Alzheimer's disease. This breakthrough opens up new possibilities for targeted drug development and better treatment options.
news
New humanised neuroinflammation in vitro platform
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
article
A novel class of drug candidates for neurodegenerative diseases
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
news
New biomarker for asymptomatic stages of Alzheimer’s disease
Researchers identified miR-519a-3p as a biomarker that could enable early diagnosis and treatment of neurodegenerative diseases.
news
Astrocytes gain neural stem cell properties after brain injury
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
news
How does the brain process and store words we hear?
US researchers studying the brain’s auditory lexicon find implications for stroke survivors and others with brain disorders.
news
Examining brain’s glymphatic system may shed light on brain diseases
US researchers used focused ultrasound with microbubbles to examine glymphatic system of the brain, which plays a crucial role in clearing metabolic waste from the brain.
article
Five recent CRISPR drug target discoveries
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
article
Developing bioenergetic nanocatalysts, a novel approach to treat neurodegeneration
Mark Mortenson, CSO of Clene Nanomedicine, discusses the use of proprietary gold nanocrystals as catalysts to prevent the progression of, and act as a treatment for, neurodegenerative disease.
article
The Editors’ views: Drug Target Review’s 2020 round-up
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
article
A novel blood-brain barrier model for cerebral malaria research
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
article
Could GPCRs be causing people to respond differently to the same drug?
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
news
Stem cell therapy repairs Parkinson’s degeneration in mice
Researchers demonstrate that transplanting dopaminergic neurons grown from stem cells into the brains of mice improved motor skills.
news
Disrupted RNA transportation results in neurodegeneration
Researchers report that reduced TDP-43 expression disrupts axonal transport of messenger RNAs to cause neurodegeneration in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).